Titre : Régions déterminant la complémentarité

Régions déterminant la complémentarité : Questions médicales fréquentes

Termes MeSH sélectionnés :

Gain of Function Mutation
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Régions déterminant la complémentarité : Questions médicales les plus fréquentes", "headline": "Régions déterminant la complémentarité : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Régions déterminant la complémentarité : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-06", "dateModified": "2025-03-03", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Régions déterminant la complémentarité" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Région variable d'immunoglobuline", "url": "https://questionsmedicales.fr/mesh/D007135", "about": { "@type": "MedicalCondition", "name": "Région variable d'immunoglobuline", "code": { "@type": "MedicalCode", "code": "D007135", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "G02.111.570.060.425" } } }, "about": { "@type": "MedicalCondition", "name": "Régions déterminant la complémentarité", "alternateName": "Complementarity Determining Regions", "code": { "@type": "MedicalCode", "code": "D022801", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Boris I Chobrutskiy", "url": "https://questionsmedicales.fr/author/Boris%20I%20Chobrutskiy", "affiliation": { "@type": "Organization", "name": "Department of Internal Medicine, Oregon Health and Science University Hospital, Portland, Oregon, USA." } }, { "@type": "Person", "name": "George Blanck", "url": "https://questionsmedicales.fr/author/George%20Blanck", "affiliation": { "@type": "Organization", "name": "Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA." } }, { "@type": "Person", "name": "Elena S Klimtchuk", "url": "https://questionsmedicales.fr/author/Elena%20S%20Klimtchuk", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Daniele Peterle", "url": "https://questionsmedicales.fr/author/Daniele%20Peterle", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Lawreen H Connors", "url": "https://questionsmedicales.fr/author/Lawreen%20H%20Connors", "affiliation": { "@type": "Organization", "name": "" } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A point mutation in recC associated with subclonal replacement of carbapenem-resistant Klebsiella pneumoniae ST11 in China.", "datePublished": "2023-04-28", "url": "https://questionsmedicales.fr/article/37117217", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41467-023-38061-z" } }, { "@type": "ScholarlyArticle", "name": "Eosinophilic solid and cystic renal cell carcinoma with TSC2 mutation: a case report and literature review.", "datePublished": "2023-04-25", "url": "https://questionsmedicales.fr/article/37098579", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s13000-023-01341-9" } }, { "@type": "ScholarlyArticle", "name": "Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer.", "datePublished": "2023-04-17", "url": "https://questionsmedicales.fr/article/37092128", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2147/JIR.S394894" } }, { "@type": "ScholarlyArticle", "name": "Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis.", "datePublished": "2023-04-14", "url": "https://questionsmedicales.fr/article/37059713", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41420-023-01413-1" } }, { "@type": "ScholarlyArticle", "name": "Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer.", "datePublished": "2023-04-14", "url": "https://questionsmedicales.fr/article/37059804", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41416-023-02264-4" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Phénomènes chimiques", "item": "https://questionsmedicales.fr/mesh/D055598" }, { "@type": "ListItem", "position": 3, "name": "Phénomènes biochimiques", "item": "https://questionsmedicales.fr/mesh/D001669" }, { "@type": "ListItem", "position": 4, "name": "Région variable d'immunoglobuline", "item": "https://questionsmedicales.fr/mesh/D007135" }, { "@type": "ListItem", "position": 5, "name": "Régions déterminant la complémentarité", "item": "https://questionsmedicales.fr/mesh/D022801" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Régions déterminant la complémentarité - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Régions déterminant la complémentarité", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Régions déterminant la complémentarité", "description": "Comment identifier les CDR dans un anticorps ?\nQuels tests révèlent la présence de CDR ?\nLes CDR peuvent-ils être visualisés ?\nQuel rôle joue la bioinformatique dans l'étude des CDR ?\nLes CDR sont-ils spécifiques à chaque anticorps ?", "url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Gain+of+Function+Mutation&page=999#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Régions déterminant la complémentarité", "description": "Quels symptômes indiquent une réponse immunitaire anormale ?\nLes CDR affectent-ils les symptômes d'infections ?\nComment les CDR influencent-ils les maladies allergiques ?\nLes CDR sont-ils liés à des symptômes de maladies auto-immunes ?\nPeut-on prédire des symptômes grâce aux CDR ?", "url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Gain+of+Function+Mutation&page=999#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Régions déterminant la complémentarité", "description": "Comment prévenir les maladies liées aux CDR ?\nLes CDR peuvent-ils être ciblés pour la prévention ?\nQuel rôle joue l'alimentation dans la prévention des maladies liées aux CDR ?\nLes tests génétiques aident-ils à prévenir les maladies liées aux CDR ?\nComment le mode de vie influence-t-il la prévention des maladies ?", "url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Gain+of+Function+Mutation&page=999#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Régions déterminant la complémentarité", "description": "Comment les CDR sont-ils utilisés en thérapie ?\nLes traitements ciblant les CDR sont-ils efficaces ?\nQuels types de médicaments ciblent les CDR ?\nLes CDR peuvent-ils être modifiés pour améliorer les traitements ?\nQuels sont les effets secondaires des traitements ciblant les CDR ?", "url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Gain+of+Function+Mutation&page=999#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Régions déterminant la complémentarité", "description": "Quelles complications peuvent survenir avec des CDR défectueux ?\nLes CDR sont-ils impliqués dans des complications infectieuses ?\nComment les CDR affectent-ils les traitements anticancéreux ?\nLes complications liées aux CDR peuvent-elles être traitées ?\nQuels sont les risques de complications lors de thérapies ciblant les CDR ?", "url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Gain+of+Function+Mutation&page=999#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Régions déterminant la complémentarité", "description": "Quels facteurs augmentent le risque de maladies liées aux CDR ?\nL'âge influence-t-il le risque lié aux CDR ?\nLe stress a-t-il un impact sur les CDR ?\nLes infections antérieures influencent-elles les CDR ?\nComment le mode de vie affecte-t-il les CDR ?", "url": "https://questionsmedicales.fr/mesh/D022801?mesh_terms=Gain+of+Function+Mutation&page=999#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les CDR dans un anticorps ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les CDR sont identifiés par séquençage et analyse des structures d'anticorps." } }, { "@type": "Question", "name": "Quels tests révèlent la présence de CDR ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'affinité et de liaison aux antigènes sont utilisés pour détecter les CDR." } }, { "@type": "Question", "name": "Les CDR peuvent-ils être visualisés ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, par des techniques comme la cristallographie aux rayons X ou la RMN." } }, { "@type": "Question", "name": "Quel rôle joue la bioinformatique dans l'étude des CDR ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "La bioinformatique aide à prédire et modéliser les CDR à partir de séquences d'anticorps." } }, { "@type": "Question", "name": "Les CDR sont-ils spécifiques à chaque anticorps ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, chaque anticorps a des CDR uniques qui déterminent sa spécificité." } }, { "@type": "Question", "name": "Quels symptômes indiquent une réponse immunitaire anormale ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des allergies ou des maladies auto-immunes peuvent survenir." } }, { "@type": "Question", "name": "Les CDR affectent-ils les symptômes d'infections ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des CDR efficaces peuvent réduire la gravité des symptômes d'infections." } }, { "@type": "Question", "name": "Comment les CDR influencent-ils les maladies allergiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des CDR spécifiques peuvent reconnaître des allergènes, entraînant des réactions." } }, { "@type": "Question", "name": "Les CDR sont-ils liés à des symptômes de maladies auto-immunes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des CDR mal régulés peuvent cibler des tissus sains, provoquant des symptômes." } }, { "@type": "Question", "name": "Peut-on prédire des symptômes grâce aux CDR ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des études sur les CDR peuvent aider à prédire la réponse immunitaire et les symptômes." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées aux CDR ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La vaccination et l'éducation sur les allergies peuvent aider à prévenir ces maladies." } }, { "@type": "Question", "name": "Les CDR peuvent-ils être ciblés pour la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des stratégies de vaccination ciblant les CDR peuvent prévenir certaines infections." } }, { "@type": "Question", "name": "Quel rôle joue l'alimentation dans la prévention des maladies liées aux CDR ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut renforcer le système immunitaire et prévenir les maladies." } }, { "@type": "Question", "name": "Les tests génétiques aident-ils à prévenir les maladies liées aux CDR ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les risques et guider la prévention." } }, { "@type": "Question", "name": "Comment le mode de vie influence-t-il la prévention des maladies ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant exercice et gestion du stress, aide à prévenir les maladies." } }, { "@type": "Question", "name": "Comment les CDR sont-ils utilisés en thérapie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les CDR sont ciblés pour développer des anticorps thérapeutiques contre des maladies." } }, { "@type": "Question", "name": "Les traitements ciblant les CDR sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils montrent une efficacité dans le traitement de diverses maladies, y compris le cancer." } }, { "@type": "Question", "name": "Quels types de médicaments ciblent les CDR ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des anticorps monoclonaux et des inhibiteurs de points de contrôle immunitaire ciblent les CDR." } }, { "@type": "Question", "name": "Les CDR peuvent-ils être modifiés pour améliorer les traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la modification des CDR peut augmenter l'affinité et la spécificité des anticorps." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des traitements ciblant les CDR ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des réactions immunitaires indésirables et des allergies." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des CDR défectueux ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des CDR défectueux peuvent entraîner des maladies auto-immunes et des allergies." } }, { "@type": "Question", "name": "Les CDR sont-ils impliqués dans des complications infectieuses ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des CDR inefficaces peuvent aggraver les infections et retarder la guérison." } }, { "@type": "Question", "name": "Comment les CDR affectent-ils les traitements anticancéreux ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des CDR mal ciblés peuvent réduire l'efficacité des traitements anticancéreux." } }, { "@type": "Question", "name": "Les complications liées aux CDR peuvent-elles être traitées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements ciblés peuvent gérer les complications associées aux CDR." } }, { "@type": "Question", "name": "Quels sont les risques de complications lors de thérapies ciblant les CDR ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent des réactions immunitaires indésirables et des effets secondaires graves." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de maladies liées aux CDR ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme la génétique, l'environnement et le mode de vie augmentent le risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque lié aux CDR ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut affecter la fonction des CDR et augmenter le risque de maladies." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur les CDR ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut altérer la réponse immunitaire et affecter les CDR." } }, { "@type": "Question", "name": "Les infections antérieures influencent-elles les CDR ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des infections passées peuvent modifier la structure et la fonction des CDR." } }, { "@type": "Question", "name": "Comment le mode de vie affecte-t-il les CDR ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain peut améliorer la fonction des CDR et réduire le risque de maladies." } } ] } ] }

Sources (10000 au total)

Eosinophilic solid and cystic renal cell carcinoma with TSC2 mutation: a case report and literature review.

Eosinophilic solid and cystic renal cell carcinoma (ESC-RCC) is an under-recognized, emerging new entity of sporadic renal neoplasms, which is listed as a rare type of renal cell carcinoma in the 2022... We report one case of ESC-RCC, a 53-year-old female patient with a right kidney mass found during clinical examination. The patient experienced no discomforting symptoms. Computer-tomography imaging a... The distinct morphological, immunophenotypic, and molecular characteristics of ESC-RCC we describe here, based on our case and the relevant literature, highlight the key points of the pathological and...

Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer.

In recent years, tumour immunotherapy has ushered in a new era of oncology treatment. However, the use of immune checkpoint inhibitors (ICIs) in the treatment of CRC remains limited. There is an urgen... We collected mutational and clinical data from cohorts of CRC patients treated with ICIs. The relationship between NOTCH pathway mutations (NOTCH-MT) and CRC immunotherapy prognosis was analysed using... We observed greater infiltration of M1 macrophages, CD8+ T cells, neutrophils, and activated natural killer (NK) cells with NOTCH-MT status. Immunogenicity was also significantly higher in patients wi... NOTCH-MT status was strongly associated with the prognosis of CRC patients treated with ICIs and is expected to serve as a novel biomarker and therapeutic target for CRC....

Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer.

In EGFR-mutant and MET-amplified lung cancer resistant to EGFR inhibitors, double blockade of EGFR and MET is considered as a reasonable strategy despite increasing toxicity. This study evaluated the ... We investigated the efficacy of a single MET inhibitor in EGFR-mutant, MET-amplified lung cancer cells (HCC827GR) and the matched clinical cases and patient-derived cells. Acquired resistance mechanis... Single MET inhibitor sufficiently inhibited the EGFR downstream signalling and proliferation in the HCC827GR cells. The MET-inhibitor-sensitive clones had similar EGFR mutation allele frequency as the... Single MET inhibition produced a short-lived response in EGFR-mutant and MET-amplified lung cancer. A further study of a novel combination therapy schedule is needed to achieve long-lasting efficacy a...

Anterior segment phenotypic changes in late-onset retinal degeneration with Ser163Arg mutation in CTRP5/C1QTNF5.

Late-onset retinal degeneration (L-ORD) is a rare retinal dystrophy with anterior segment (AS) abnormalities, including long anterior zonules (LAZ) and iris atrophy. This investigation evaluates AS ch... Prospective, longitudinal study including L-ORD individuals (Ser163Arg) with ocular exam and standard slit-lamp photographs between 2011 and 2022. AS images were merged and assessed for LAZ number and... Twelve eyes of 6 patients (4 males, median age = 60.5 years) were included, showing a median of 160 (11-372) LAZs, mainly localized superiorly (39%) and inferiorly (24%). There was a high inter-ocular... This study confirms symmetric LAZs count and ZFZ in L-ORD, with ZFZ measurements smaller than in previous cohorts. A reduction in LAZs count and an increase in ZFZ with age were suggested longitudinal...

Significance of FNAC, BRAF mutation, and intraoperative frozen section in surgical decision-making of thyroid nodules.

A preoperative method is desired to discriminate benign from malignant thyroid nodules. This retrospective study evaluated the diagnostic performance of BRAF (B-Raf proto-oncogene) mutation (BRAF... Patients underwent preoperative FNAC of thyroid nodules. Cytology specimens were classified according to the Bethesda System for Reporting Thyroid Cytopathology (BSRTC), and analyzed for BRAF... Among 346 patients, 333/358 FNACs (93%) showed malignant nodules; 322 (93%) patients received a pathological diagnosis of papillary thyroid carcinoma (PTC). The sensitivity and specificity of BSRTC VI... The diagnostic performance of preoperative BRAF...

RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma.

Advanced lung cancers carrying Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation remain a group that lacks effective treatments. Receptor activator of nuclear factorκB ligand (RANKL) has been... The data used to explore expression and prognosis were obtained from The Cancer Genome Atlas, Genotype-Tissue Expression databases, and from our hospital. The proliferation, invasion, and migration ca... RANKL is strongly expressed in advanced KRAS-mt LUAD, and significantly distinct association exists between high RANKL expression and poor survival. The enriched expression of RANKL in advanced KRAS-m... RANKL acts as an unfavorable prognostic biomarker for patients with advanced KRAS-mt LUAD. Inhibition of RANKL may be a feasible strategy for this subset of patients....